$600,000 in awards against ovarian cancer for Fred Hutch and UW researchers

Research awarded from the Rivkin Center and Andy Hill CARE fund will dramatically improve outcomes for ovarian cancer patients and the clinicians treating them
Photos of Drs. Megan Shen and Nora Disis
Drs. Megan Shen (left) and Nora Disis (right) are working to transform the landscape for ovarian cancer patients and their providers. Photos by Fred Hutch and UW Institute of Translational Health Science

In 2023, the Rivkin Center partnered with the Andy Hill Cancer Research Endowment (CARE) Fund to fund $1 million in grants for research institutions in Washington state to unlock answers in ovarian cancer.

This year, researchers Megan Shen, PhD, and Mary L. “Nora” Disis, MD, of Fred Hutch Cancer Center and UW Medicine respectively, have each been recently awarded $300,000 in grants under the Rivkin Center and CARE Fund partnership for projects that aim to improve outcomes of the disease. On April 1, the Rivkin Center merged with the Ovarian Cancer Research Alliance.

Shen, a social psychologist and health communication researcher, is modifying an existing support program for patients, Helping Ovarian Cancer Patients Cope (HOPE), to use with clinicians in gynecologic oncology, including oncologists, nurses and advanced practice providers. This modified program seeks to reduce burnout among clinicians through tools to manage stress and maintain resilience.

Disis, a professor of medicine at the University of Washington and director of the UW Cancer Vaccine Institute, is optimizing a novel delivery system for an ovarian cancer vaccine. The treatment aims to prevent the spread of chemotherapy-resistant strains of the disease. Both projects have the potential to dramatically improve treatment and outcomes of people with ovarian cancer.

HOPE for patients and providers

Ovarian cancer is the eighth-most common cancer for women in the U.S., but the fifth leading cause of cancer death for women, according to the National Cancer Institute. The American Cancer Society projects that nearly 21,000 women in the U.S. will be diagnosed with the disease each year.

Much of the reasoning for poor prognoses for ovarian cancer is due to late diagnoses, said Shen, an associate professor in the Fred Hutch Clinical Research Division. Symptoms like fatigue, weight loss and discomfort are vague and associated with aging and a myriad of other disorders or illnesses.

“Many patients follow a very specific trajectory,” explained Shen. “They get diagnosed late in their illness, and many of them have recurrences.”

Adding to an already difficult diagnosis, many patients expressed an overall lack of support for spaces tailored to people with ovarian cancer. In response came HOPE, an intervention to reduce hopelessness and helplessness in patients with recurrent ovarian cancer.

The program brings together colleagues at Fred Hutch (Casey Walsh, PhD); UW (Barbara Goff, MD, and Heidi Gray, MD), and non-academic partner Robyn Castellani.

In HOPE workshops, patients share the challenge and pain of their diagnosis. From there, they work with social workers and creative storytelling experts, learning techniques to manage and cope with their pain while building community and connection. According to Shen, the program is pilot testing both in person and virtual workshops to broaden access for patients and clinicians alike.

HOPE for clinicians, the new adaptation of the HOPE program, brings together small cohorts of clinicians in gynecologic oncology in weekly 90-minute workshops led by a social worker and expert in creative storytelling. HOPE for clinicians focuses on both equipping clinicians to support their patients with recurrent ovarian cancer, using the same tools and techniques in the original HOPE intervention for patients, as well as supporting them in their own burnout as clinicians. HOPE for clinicians equips clinicians on ways to give support and embeds resources that directly support clinicians themselves.  

The program teaches coping strategies centered in storytelling, the science behind them and how to share these strategies with patients. The second half of the workshop provides prompts to reflect on positive aspects in clinicians’ lives, which they share with their cohort.

“It’s a group share where they reflect on their own stories, challenges and what’s working well for them,” said Shen.

Caring for compassion fatigue

Shen shared that both patients and clinicians had requested a version designed for clinicians after the initial patient pilot workshop. While patients face the difficulty of life with ovarian cancer, their providers also face the emotional burden of providing advanced care.

“They’re facing patients who are often dying from their illness,” explained Shen. “They feel like they don’t have anything to offer when treatment options run out, and they can’t support them in a way that feels meaningful.”

What many of these providers are experiencing is a term called compassion fatigue, said Shen.

“When you're seeing patient after patient and you're having to break bad news over and over again, a coping strategy often emerges from that high level of burnout,” she explained. “In a self-protective way, you fatigue out and you feel less compassion towards your patients.”

The downstream effect of this fatigue manifests itself in the patient-provider relationship. Shen added that patients can feel this lack of empathy, and therefore less of a connection to their provider.

Compassion fatigue is a coping strategy that manifests on its own. The HOPE program addresses the feeling of emotional burnout and provides strategies and frameworks that encourage support and connection between providers and their patients, while providing a place of community and support.

A potential gold standard for vaccine delivery

Disis has spent the last decade developing vaccines for ovarian cancer. This year, she is targeting chemotherapy-resistant recurrent ovarian cancer, a form of that is particularly difficult to treat, to reduce and prevent it from metastasizing further. Disis holds the Helen B. Slonaker Endowed Professor for Cancer Research at UW.

Her research will optimize the delivery of an existing ovarian cancer vaccine that has shown promise in stalling tumor growth and increasing tumor sensitivity to chemotherapy. Her project compares the standard, needle-based injections of vaccines against an innovative method that delivers DNA on gold beads through the skin, improving mucosal immunity in collaboration with Orlance, a Seattle biotechnology company.

According to Disis, the gold bead delivery can potentially lead to a stronger response against cancer by the patient’s immune system, making it a better way to vaccinate. If this gold bead method shows an improvement against the needle-based method, these results will pave the way for clinical trials. 

Shayla Ring

Shayla Ring is an integrated marketing and communications coordinator at Fred Hutch Cancer Center. With a background in political science and communications, her work aims to reduce disinformation and promote meaningful stories. Her previous roles have also been with mission-driven organizations across the Seattle area. Reach her at sring@fredhutch.org.

read-more

Read more about Fred Hutch achievements and accolades.

Related News

All news
Dr. Filippo Milano receives inaugural Endowed Chair in Cord Blood Research Unrestricted funding will help grow Fred Hutch’s Cord Blood Transplant Program so that ‘every patient has a donor’ April 2, 2025
Drs. Keith Jerome and Jesse Bloom elected fellows of American Academy of Microbiology Fred Hutch researchers’ study of viruses evolves from basic understanding to practical applications March 20, 2025
$400,000 awarded to ovarian cancer researchers Drs. Holly Harris and Elizabeth Swisher receive Rivkin Center, Andy Hill CARE Fund grants to pursue prevention methods April 22, 2024

Help Us Eliminate Cancer

Every dollar counts. Please support lifesaving research today.